China Requires Medical Device Registration for RF Beauty Devices from April 2026: Key Impacts on Global Trade

Introduction

Starting April 1, 2026, China will enforce mandatory medical device registration (Class II NMPA certification) for all radiofrequency (RF) beauty equipment, including RF therapy devices and skin rejuvenation systems. This regulatory shift directly impacts global beauty device manufacturers, particularly those exporting to or sourcing from China, as well as EU/US importers reliant on Chinese supply chains. The policy requires immediate compliance checks for existing trade flows and factory audits under FDA 510(k) or EU MDR frameworks.

Event Overview

China's National Medical Products Administration (NMPA) has confirmed that RF beauty devices will be reclassified as Class II medical devices effective April 2026. Key confirmed details include: 1) Mandatory NMPA registration for production, export, and domestic sales; 2) Immediate prohibition of unregistered devices; 3) Requirement for international importers to update technical documentation under FDA/EU MDR standards with Chinese factory audit data.

Impacted Industry Segments

1. OEM/ODM Manufacturers

Chinese contract manufacturers serving global brands face production halts unless obtaining NMPA certification. Analysis shows 60-70% of current OEMs lack medical device manufacturing licenses, requiring 12-18 months for compliance conversion.

2. EU/US Importers

Companies importing Chinese-made RF devices must now verify suppliers' NMPA status and reconcile documentation with FDA 510(k) or EU MDR requirements. This creates dual compliance burdens for CE-marked devices previously exempt from medical classification.

3. Component Suppliers

RF generator and electrode suppliers will undergo stricter traceability requirements as medical-grade component standards apply. This may disrupt existing just-in-time delivery models.

Actionable Guidance for Businesses

1. Supplier Verification Protocol

Immediate audit of Chinese suppliers' NMPA application status is critical. Medical device registration numbers should be cross-checked via NMPA's official database (accessible in English since 2025).

2. Documentation Alignment

EU importers must update Technical Documentation under MDR Article 61(3) for equivalence claims, while US importers need supplemental 510(k) submissions reflecting factory changes.

3. Inventory Planning

Non-compliant inventory must clear customs before March 31, 2026. Consider bonded warehouse strategies for goods in transit during policy transition.

Industry Perspective

This regulatory change signals China's alignment with global medical device standards for aesthetic technologies. From an industry standpoint: 1) It reflects growing safety concerns about consumer-grade RF devices; 2) Creates potential market advantages for early compliant manufacturers; 3) May accelerate consolidation among Chinese beauty device makers. However, the 18-month transition period allows for strategic adjustments, unlike emergency regulatory actions.

Conclusion

The NMPA's reclassification represents a structural shift in global beauty device trade flows rather than temporary disruption. While increasing compliance costs short-term, it establishes clearer quality benchmarks for cross-border trade. Industry players should treat this as a catalyst for supply chain optimization rather than mere regulatory compliance exercise.

Information Sources

1. NMPA Announcement (2025/03/15) - Medical Device Classification Catalogue Update 2. FDA Guidance Document (2025-17840) - Third-Country Medical Device Equivalence 3. Ongoing monitoring required for: provincial-level implementation rules (expected Q3 2025)